Notably, the ASCVD group had a higher prevalence of myocardial infarction, while all statin-benefit groups had a higher prevalence of obesity, diabetes with chronic complications, and tobacco use but lower ACE inhibitors use in post-guideline. The gene discussed is ACE; the disease is myocardial infarction.